EasyCookieInfo

5 February 2019 - Takis announces the publication of a paper exploring current antifungal therapeutic strategies

Takis is proud to announce the publication of the article "The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?" by Di Mambro et al on Frontiers in Pharmacology.

Fungal infections are deadly diseases in immunocompromised hosts. Most importantly, fungi are becoming resistant to current treatments. Here, we summarize currently used antifungal agents and propose novel therapeutic approaches, including new fungal molecular targets to be considered for drug development.

Takis has an active program on the generation of monoclonal antibodies against Aspergillus Fumigatus and other species. We set up a rodent model of Invasive Aspergillosis, which is suitable for the evaluation of new drugs and combination with existing standard of care.

Full article available at: The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?

27 February – 1 March 2019 – Takis is a sponsor of the 1st VITARES Annual Meeting, Rome, Italy

Takis is glad to sponsor the first Vitares Annual Congress, which is also the first Italian One Health meeting focusing on Cancer Immunotherapy.

This meeting brings together Basic research, Veterinary and Human Medicine Scientists involved in the field of Immunology, Oncology and Education, aiming at creating networks of collaboration. Internationally renowned scientists from Italy and abroad will provide the State of the Art and present their most recent data in a highly stimulating scientific environment.

Public health initiatives such as One Health demonstrate the growing awareness of the fact that animal and human health are strongly interconnected with each other and with the environment. Zoonotic pathogens and Cancer represent a direct hazard to Veterinary and Human Health”, said Luigi Aurisicchio, CEO/CSO at Takis and president at Vitares.

Looking forward to meeting you in Rome!

 

 

6 February 2019 – Takis publishing data on personalized neoantigen vaccine platform

We are proud to announce the first POC data achieved in advanced preclinical models with our personalized vaccine platform based on NeoAntigen Identification/DNA Electroporation and published on Journal of Experimental & Clinical Cancer Research.

 

We have developed different neoantigen minigene vaccine vectors to determine the rules for a successful neoantigen cancer vaccine delivered by plasmid DNA and electroporation. We found that a strong poly-functional and poly-specific immune response was observed with high affinity neoantigens. Our pipeline - from the selection of neoantigens to vaccine design – was also applied to a new model of patient derived tumor xenograft resulting in therapeutic treatment.

These results suggest a feasible strategy for a neoantigen cancer vaccine that is simple and applicable for clinical developments.

Read the full article: https://doi.org/10.1186/s13046-019-1084-4

December 2018 - Takis coordinates the project REVER3MAB

Takis is coordinating the project REVER3MAB, in collaboration with Istituto Regina Elena IRCCS and IBI – Istituto Biochimico Lorenzini, for the development of an anticancer monoclonal antibody aimed at "reverting" resistance to conventional oncological therapies.

The acronym "REVER3MAB" identifies a monoclonal antibody, directed against the ErbB3 protein able to block the proliferation of tumor cells in vitro and in vivo, with potential use as a therapeutic agent in the clinic.
Goals of the project are the optimization of the drug for clinical experimentation, its production on industrial scale and the setting-up of widely applicable humanized tumor models, the ImmunoAvatars. Counting on our expertise, we really expect to make a difference in the lives of cancer patients.

4-5 December 2018, Takis and Evvivax at BioFIT, Lille, France

Dr. Luigi Aurisicchio, CEO/CSO at Takis and Evvivax flew to Lille to represent both the companies at BioFIT 2018. This is the place where academia-industry collaborations get started, an exceptional platform for tech transfer and partnership building.

Luigi Aurisicchio took part in a round-table discussing the translational potential of veterinary medicine to complement current human Immune-Oncology approaches in the next future.
“I was honoured to contribute to the discussion with Takis/Evvivax experience and biotech perspectives. The possibility to work both in the human and animal health space provides a truly unique position and allows to appreciate two different worlds which converge into the One health approach”, declared Luigi Aurisicchio.
We hope that common grounds in human and animal health could lead to more frequent and translationally relevant collaborations all over the world.

14-16 November 2018 – Takis attends NeoAg Summit, Boston

The NeoAg Summit is the annual industry focused meeting dedicated to advancing neoantigen based cancer vaccines and cell therapies. The meeting brings together research groups and companies from all over the world working on neo-antigens, with the aim of exchanging ideas and results to overcome current limitations and accelerate safe, effective and scalable neoantigen-based therapies.

There in Boston, we found an exceptional platform to discuss the promises and challenges of an ever-expanding field of research. This experience has strengthened our determination to pursue the aim of realizing individualised therapeutic vaccines targeting tumor neoantigens in patients. We bet on personalized medicine, as we aware of the enormous benefits that could bring to patients.